Top-selling drugs might be first in line for Medicare price negotiations

Should Medicare be allowed to square off with pharma on drug prices? Presidential candidate Hillary Clinton was the latest politician to propose it, joining Democratic rival Sen. Bernie Sanders, President Obama--and a variety of other lawmakers before them.

Hillary Clinton plan to curb drug prices puts the screws to drugmakers and insurers

Presidential candidate Hillary Clinton unloaded on both the drug and insurance industries on Tuesday with proposals to help protect consumers from rapidly escalating drug prices. While most are unlikely to ever become a reality, the suggestions for price caps on consumer copays and a mandate on what drugmakers must spend on R&D turned up the heat on the debate over rising prices.

EP Vantage: Legal loopholes, price hikes set up aging meds for billions in 2020

In the land of pharma, off-patent drugs usually translate to lost profits. But things don't always shake out that way, according to a new report from EvaluatePharma, which found that companies with aging blockbusters could be set to collect billion-dollar sales for the meds by 2020.

Novo Nordisk strikes deal with Iran government to produce insulin pens in the country

Novo Nordisk will step up its operations in Iran, saying today it will build a €70 million ($78.1 million) plant to produce its FlexPen prefilled devices to better supply the country with its insulin products.

Clinton backs Medicare negotiation, copay caps in assault on pharma pricing

On Monday, Hillary Clinton spooked biotech investors with a tweet promising to crack down on high drug prices. Shares plummeted. On Tuesday, she'll publicly unveil her pricing proposals in an Iowa speech, but until then, her campaign has offered some quick hints.

Valeant's latest tax-cutting tactic, courtesy of Luxembourg

Valeant is famous for wringing cost savings out of its buyouts, and its tax-advantaged Canadian domicile helps on that front. Now, it's leveraging another address to pare down Salix's tax bill by more than $560 million. But how?

J&J faces Tylenol lobbying allegations in first case to go to trial over med

New court documents in the first trial over claims that Johnson & Johnson promoted its blockbuster painkiller, Tylenol, without disclosing potentially dangerous side effects show that J&J's McNeil Consumer Healthcare unit planned to lobby government officials to prevent the FDA from implementing safety restrictions, ProPublica reports.

Rough waters for pharma's U.S. pricing power, yes. Sea change? Nope

This could go down in pharma history as the week that drug pricing met pop culture. But this week won't be remembered as the one when drugmakers lost their long-standing pricing power in the U.S. That, at least, was the word from analysts and at least one top pharma CEO as politicians vowed a crackdown.

HIV activists join Janssen's story-focused Prezcobix effort

Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with the disease.

Thanks, Turing. Your 5000% price hike puts pharma in the election hot seat

The ongoing controversies over rising drug prices have most Americans blaming drugmakers for their own rising pharmacy bills. The last thing pharma needs right now is a scandalous price hike to turn up the heat even further. But that's just what Turing Pharma and its CEO, Martin Shkreli, have on offer.

New ulcerative colitis data could help Pfizer's Xeljanz pick up the pace

Rheumatoid arthritis therapy Xeljanz hasn't gotten off to the start Pfizer hoped, but new indications could give it a boost. On that front, the company reported positive results on Monday from a pair of trials evaluating the med in ulcerative colitis.

Bayer sets up triumvirate of managers to run slimmed-down operation

Change is coming for Bayer--and with it, change at the top. The German pharma has outlined its plans for retooling, post-plastics division divestment--and they involve three operational arms, each headed up by a company vet.

Hillary Clinton to lay out her plan for cutting drug prices

Senator, and presidential candidate, Bernie Sanders and his cohort, Rep. Elijah Cummings, have gotten a lot of attention for their proposed legislation to cut spiraling drug prices in the U.S. One person who seems to have noticed is Hillary Clinton, who says she will unveil her own plan this week for controlling the "cost of skyrocketing prescription drugs."

Bloomberg: Sanofi, Pfizer mull potential deal for Mexican generics maker Rimsa

Big Pharma is having a dealmaking fiesta in Mexico, with companies such as Sanofi, Pfizer and Teva Pharmaceutical Industries considering buying local generic drugmaker Representaciones e Investigaciones Medicas, also known as Rimsa, to beef up business south of the border.

Intas CEO expects to break into U.S. biosimilar market yet this year

The CEO of Intas Pharmaceuticals expects his company to get FDA approval this year for its biosimilar of Amgen's Neulasta, a drug it developed with Canada's Apotex.

Novartis CEO stands by emerging markets even as China economy continues to weaken

China's economy is a mess and other emerging markets are flailing about as well. So what is pharma CEO to do if they have bet big on growth in the EM realm? Keep on keeping on, says Novartis CEO Joe Jimenez.

Perrigo CEO has slammed Mylan for months--but he owns its shares

Perrigo CEO Joseph Papa has cautioned investors against taking up an offer from hostile suitor Mylan. But Papa is already a Mylan shareholder himself.

UPDATED: FDA asks Pfizer for Zoloft label update highlighting birth defect risks

For years, Pfizer has shrugged off claims that its antidepressant Zoloft causes heart defects in newborns, fighting a raft of litigation alleging that the company did not adequately warn pregnant women taking the med about its potential risks. Now the FDA is weighing in on the issue, asking the company to acknowledge some studies that link Zoloft to heart defects in babies.

Allergan and Richter's antipsychotic gets FDA OK but faces stiff competition

On Thursday, Allergan snagged FDA approval for a sort-of-new antipsychotic, Vraylar, to treat schizophrenia and bipolar disorder in adults. But after about a two-year delay in which a raft of antipsychotics--both generic and branded--have made it to market, the question is where it will find a place of its own.

Lilly, BI's Jardiance posts 'amazing' 14% reduction in major CV events

Since Eli Lilly and Boehringer Ingelheim announced that their SGLT2 med, Jardiance, had become the first to show it could lower the risk of major cardiovascular events, the question on the minds of industry watchers has been "How much?"